# Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis

> **NCT03164018** · — · COMPLETED · sponsor: **Genesis Pharma CNS & Specialty** · enrollment: 111 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Fampridine

## Key facts

- **NCT ID:** NCT03164018
- **Lead sponsor:** Genesis Pharma CNS & Specialty
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-07
- **Primary completion:** 2018-12-15
- **Final completion:** 2018-12-15
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164018, "Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03164018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*